Asarfi Hospital cuts margin targets and delays capacity expansion
Management lowered EBITDA margin guidance to 23-25% and pushed its 500-bed capacity goal to 2028. The company cited no specific reason for the shift.
What's new
- EBITDA margin guidance dropped to 23-25% from 25-27%.
- 500-bed capacity target deferred by one year to 2028.
- Bone marrow transplant unit delayed 4-5 months pending state policy approval.
Why this matters
The combination of margin compression and deferred capacity expansion suggests execution headwinds that management has yet to fully clarify. While revenue growth targets remain ambitious at 50%, the lack of transparency regarding the one-year delay in the 500-bed roadmap is a red flag for investors.
What we're watching
- Closure of the nearly settled hospital acquisition.
- State government policy approval for the bone marrow transplant unit.
- Actual revenue performance against the ₹250-260 crore FY27 target.
The full read
Asarfi Hospital is recalibrating its growth path. During its May 27, 2026, conference call, management lowered its medium-term EBITDA margin target to 23-25% from the previous 25-27% range. The company also pushed its 500-bed capacity goal back by one year to 2028 without providing a clear explanation for the delay. While the company is targeting ₹250-260 crore in revenue for FY27—a 50% jump from the ₹173.5 crore recorded in FY26—that projection relies partly on an acquisition that is nearly settled but not yet closed. Operational progress continues in pockets, with cancer hospital revenue up 65% to ₹33 crore and new equipment like the Philips Azurion Cath lab coming online. However, the bone marrow transplant unit remains stalled for 4-5 months pending state policy approvals. The open question is whether the inorganic growth can offset the margin compression and the slower pace of capacity expansion.
Questions answered
- What is the new revenue guidance for FY27?
- Management expects revenue of ₹250-260 crore, which represents a 50% increase over the ₹173.5 crore reported in FY26.
- Why was the bone marrow transplant unit delayed?
- The unit is facing a 4-5 month delay while waiting for necessary policy approvals from the state government.
- What is the status of the planned hospital acquisition?
- Management described the deal as nearly settled during the call but confirmed it has not yet closed.
- What operational updates were mentioned?
- The company installed a new nuclear medicine SPECT camera and operationalized a Philips Azurion Cath lab in March 2026.